Prostate-specific antigen — to screen or not to screen?

The biggest controversy in prostate screening is that some prostate cancers grow slowly and would never cause any problems.

Because of an elevated PSA, men may be diagnosed and treated with surgery or radiation for lesions that would never have caused symptoms or led to their death — and these treatments have side effects that can seriously affect a man's quality of life.

Essentials frames it more broadly: there is great controversy around the efficacy of active screening for prostate and breast cancer in older persons, because although incidence rises with age, the rate of tumour growth may be slower.

This is therefore a disease where screening can cause net harm — the classic example of overdiagnosis leading to overtreatment.

No major scientific or medical organisation supports routine testing for prostate cancer — including the ACS, American Urological Association (AUA), USPSTF, American Academy of Family Physicians, and American College of Preventive Medicine.

ACS: beginning at age 50, men at average risk with a life expectancy of at least 10 years should have a conversation with their provider about the benefits and limitations of PSA testing and make an informed decision based on personal values and preferences.

NCCN: focuses on men at increased risk because of family history and race, and states that PSA testing should only be offered to men with a life expectancy of 10 or more years.

USPSTF (as quoted in Pathy's): recommends against prostate cancer screening in men 70 and older.

Older USPSTF grades (Essentials table): "I" (insufficient evidence) for men younger than 75 and "D" (recommends against) for men aged 75 or older.

Note the policy discrepancy highlighted in Essentials: Medicare will pay for PSA screening even though the USPSTF does not recommend it.

Essentials records that the USPSTF recommendation not to screen men older than 75 "unleashed a firestorm of controversy" — worth quoting in a viva.

All organisations emphasise the need for the clinician to discuss possible benefits and side effects of treatment, so that men aged at least 50 (younger if at higher risk) can make informed decisions.

PSA by category: "Discuss pros and cons with the patient" in the Robust and the Frail; "Discuss pros and cons with the caregiver" in the Moderately demented; nothing at End of life.

Examination point: PSA is the only cancer screening test Pathy's carries into the demented category — and even then the recommended action is a conversation, not a test. The intervention here is shared decision-making itself.

The "10-year rule" is central — both ACS and NCCN make life expectancy of ≥10 years the entry criterion, because prostate cancer has a long natural history and the lag time to mortality benefit is long.

Benign prostatic hyperplasia is a major confounder — Pathy's notes prostatic hyperplasia is present in one in three men over the age of 70, and it raises PSA independently of cancer.

Other non-malignant causes of a raised PSA: prostatitis, urinary tract infection, urinary retention, catheterisation, recent instrumentation, digital rectal examination, ejaculation and cycling. 5-alpha-reductase inhibitors halve the PSA, so the measured value must be doubled.

The harm cascade must be explained explicitly: PSA → biopsy (bleeding, pain, sepsis) → overdiagnosis → radical treatment.

Treatment harms are geriatrically important: Pathy's states that prostate cancer treatment, including surgery, radiotherapy and brachytherapy, can cause urinary incontinence and erectile dysfunction, and that prostate cancer survivors report high levels of concern about sexual health, particularly about satisfying their partners.

The decisive geriatric question is not "how old is he?" but "if the PSA is raised, will he accept a biopsy, and if cancer is found, would he accept treatment?" If the answer is no, the test should not be done.

ERSPC — the definitive trial — now has 23-year follow-up. The final ERSPC analysis (NEJM, 2025) covered a predefined core age group of 162,236 men aged 55–69 across eight European countries, randomised to repeated PSA testing or no invitation, with prostate cancer mortality as the primary outcome. Long-term follow-up confirms a sustained reduction in prostate cancer deaths with an improved harm–benefit ratio, and the authors conclude that future screening should adopt risk-based approaches to minimise overdiagnosis while maintaining benefit. At 23 years the relative reduction in prostate cancer–specific mortality was 13% (RR 0.87, 95% CI 0.80– 0.95), an absolute risk reduction of 0.22%.

The Rotterdam arm gives the most quotable numbers. At a median follow-up of 21 years, the rate ratio for prostate cancer–specific mortality was 0.73 (95% CI 0.61–0.88) favouring screening, with a number needed to invite of 246 and a number needed to diagnose of 14 to prevent one prostate cancer death (European Urology, 2023).

The updated systematic review, including the UK CAP trial, gives a more sober estimate. The latest review added the UK CAP trial (2002–2021, 15 years of follow-up) and up to 23 years of ERSPC data; in sensitivity analyses based mainly on ERSPC, PSA screening was associated with a 13% relative reduction in prostate cancer mortality (RR 0.87, moderate-certainty evidence), with ERSPC judged to have the lowest risk of bias. Repeated PSA screening reduces prostate cancer–specific mortality and metastatic disease but has no effect on all-cause mortality, and the benefit increases with longer follow-up. The single most important new number for a geriatrics answer Overdiagnosis rises steeply with age. Using 15-year follow-up from the CAP randomised trial and English competing-mortality rates, men diagnosed at age 50 had a 16% chance that the cancer would not have been detected within 15 years; this rose to 32% at age 70 and 58% at age 80. In other words, more than half of screen-detected prostate cancers in an 80-year-old are overdiagnosis.

Treatment choice matters less than was assumed — the ProtecT 15-year results. In ProtecT (NEJM, 2023), men with localised, PSA-detected prostate cancer randomised to active monitoring, radical prostatectomy or radiotherapy had essentially identical prostate cancer mortality at 15 years (around 3% in all three arms), though metastasis and progression were commoner with monitoring. This substantially weakens the argument that early detection must be followed by radical treatment, and strengthens the case for active surveillance in older men.

The screening pathway is being redesigned around MRI, not PSA alone. The ProScreen trial (JAMA, 2024) uses a stepwise pathway — PSA ≥3 ng/mL → four-kallikrein panel → mpMRI if score ≥7.5% → biopsy if PI-RADS ≥3, with screening intervals of 2, 4 or 6 years depending on the PSA level; mortality analyses are planned at 10 and 15 years. The randomised PROSA trial (European Urology, 2025) found an MRI-first pathway detected clinically significant cancer in 4.6% versus 1.8% with a PSA-based strategy — a 2.5-fold increase — without increasing detection of low-grade (Grade Group 1) disease. A contrast-free MRI-first strategy therefore improves detection of clinically significant prostate cancer without increasing overdiagnosis or biopsy rates. This builds on PRECISION (2018), in which 28% of men randomised to MRI-targeted biopsy avoided biopsy altogether while 12% more clinically significant cancers were detected than with standard TRUS biopsy.

A definitive answer is being sought. The TRANSFORM trial, announced May 2024 and backed by a £42 million grant, is one of the largest screening studies ever, involving over a quarter of a million men followed for more than 10 years, aiming to increase detection of life-threatening cancer while reducing unnecessary biopsies and overtreatment. It will invite men aged 50–75, or 45–75 for Black men, and test four approaches including 12-minute fast MRI, genetic testing and PSA, with early results not expected before 2028.

Where policy currently stands. Most countries recommend against population-based prostate screening despite the ERSPC results, because harms may outweigh benefits; the UK National Screening Committee voted against PSA-alone screening in 2020. The USPSTF position is unchanged since 2018: shared decision-making for men 55–69 (grade C) and against screening in men 70 and older (grade D). India has no national prostate screening programme; testing is entirely opportunistic and privately funded.

Immunization — Numbers to Quote Item Figure Influenza deaths >90% occur in adults ≥65 Influenza vaccine ↓ influenza risk ~50%; ↓ influenza mortality ~70%; only ~40% effective vs clinical illness in nursing homes Herd protection Vaccinating >80% of nursing-home residents prevents outbreaks Nichol 2007 (Essentials) HR 0.75 for pneumonia/influenza hospitalisation; HR 0.52 for death CAPITA PCV13 ↓ vaccine-type pneumococcal pneumonia by 45% Zoster vaccines Zostavax 30% protective; Shingrix ~90% protective Post-herpetic neuralgia >40% of those over 60; zoster in up to 50% by age 85 Tetanus >50% of cases occur in people ≥60 AReSVi-006 (RSV) 82.6% season 1; 94.6% with comorbidity; 62.9% cumulative over 3 seasons; 48% in season 3 DANFLU-2 332,438 adults ≥65; primary endpoint neutral; cardiorespiratory hospitalisation 2.25% vs 2.38% Zoster & dementia (Wales) ~20% reduction in new dementia diagnoses over 7 years; uptake jump 0.01% → 47.2% Zoster & cardiovascular 23% lower risk of cardiovascular events PCV21 Covers ~85% of IPD in ≥50s vs ~59% for PCV20; lacks serotype 4 PCV20 real-world VE IPD 25.6% overall (35.4% at 65–74; 24.0% at 75–84; 16.6% at ≥85); all-cause pneumonia 15.2% 2. Immunization — Age Thresholds (Current)

Travel Vaccination — Key Facts Item Figure / rule Pre-travel consult 4–6 weeks before departure YF certificate Valid 10 days after vaccination; now valid for life; India — 6 days' quarantine if absent YF and age ≥60 Precaution, not contraindication YEL-AND 0.8/100,000 doses overall; 2.2/100,000 at ≥60 YEL-AVD Multi-organ failure, ~48% mortality; 6× higher in the elderly Serious AEs in elderly 3× higher overall; 5× higher above 70 Hajj / Umrah Meningococcal ACWY required, ≥10 days before arrival, valid 3–5 years Rabies PrEP 2 doses — day 0 and day 7 Japanese encephalitis Stay ≥1 month in rural endemic area; age itself is a risk factor for severe JE Hepatitis A in India Check anti-HAV IgG first — most older Indians already immune 4. Cancer Screening — Age Cut-offs Cancer Pathy's / textbook Current (USPSTF) Breast Mammography 1–2 yearly: Robust to 80, Frail to Biennial 40–74 (B); ≥75 insufficient (I)

Cancer Screening — Trials and Numbers Trial / source Result NordICC (NEJM 2022) 10 y: CRC 0.98% vs 1.20% = 18% ↓ incidence; no mortality benefit; uptake 42%; per-protocol 31% / 50% NordICC (Lancet 2026) 13 y: incidence reduced, mortality still not; 30% of endoscopists below ADR of 25% ECLIPSE / Shield 83% sensitivity for CRC; 90% specificity; only 13.2% for advanced adenoma; FDA approved 29 July 2024 FOBT (Pathy's) Sensitivity 82% MASAI (Lancet 2026) 105,934 women; +29% detection, −44% workload, −12% interval cancers; sensitivity 80.5% vs 73.8% at specificity 98.5% Mammography ≥70 meta- 28% ↓ breast cancer mortality (RR 0.72); overdiagnosis ~19% analysis ERSPC (NEJM 2025) 162,236 men aged 55–69; 23 y: 13% relative, 0.22% absolute ↓ prostate cancer mortality ERSPC Rotterdam (2023) 21 y: RR 0.73; NNI 246, NND 14 CAP overdiagnosis analysis Overdiagnosis 16% at 50 → 32% at 70 → 58% at 80 ProtecT (NEJM 2023) 15 y: ~3% prostate cancer mortality in all three arms (monitoring, surgery, radiotherapy) PROSA (Eur Urol 2025) MRI-first detected csPCa 4.6% vs 1.8%, no rise in GG1 disease PRECISION (2018) 28% avoided biopsy; 12% more clinically significant cancers detected TRANSFORM >250,000 men; £42 million; results not before 2028 LDCT ↓ lung cancer mortality ~20% vs chest X-ray

Indian Data — Must-Quote Figures Item Figure LASI Wave 1 (n = 31,464, ≥60) DT 2.75%; typhoid 1.84%; hepatitis B 1.82%; influenza 1.59%; pneumococcal 0.74% Adult vaccine coverage overall <3% for most vaccines in older adults Influenza uptake ≥45 y ≤2% (IJMR rapid review, 2024) Hepatitis B in healthcare workers Only 55–64% (Delhi, Mumbai) Invasive pneumococcal disease CFR 20–25% at ≥65 vs 5–10% in younger adults Herpes zoster lifetime risk ~30%, rising to ~50% by age ≥85 Cancer burden Breast + cervix + oral ≈ 34% of all cancers in India NP-NCD screening Oral, breast, cervical — free at AAMs, ages 30–65 only; VIA-based Cervical screening coverage 10.18 crore of 25.42 crore eligible women screened (July 2025); but <2% of women 30–49 screened at NFHS 2019–21 National Cancer Grid VIA 1–3× lifetime (low resource); HPV q10y (enhanced); HPV q5y at 25–65 (high resource) ICMR breast screening Clinical breast examination every 1–3 years Programme gaps Adult vaccines outside UIP and NPHCE; no CRC or prostate screening programme; no cancer screening at all above 65 The Five Sentences That Carry This Whole Topic

In geriatrics, prevention is governed by life expectancy versus lag time to benefit, not by chronological age.

Immunosenescence means older adults need higher-antigen, adjuvanted or recombinant vaccines — and paradoxically the frailest gain most from preventing hospitalisation while responding least immunologically.

The global immunization framework has moved from age-based schedules to life-course, risk-profile immunization; age thresholds for pneumococcal, zoster and RSV have all fallen to 50.

Cancer screening in the old is limited less by the test's accuracy — which often improves with age — than by competing mortality and overdiagnosis.

In India the limiting factor is not the guideline but the programme: adult vaccines lie outside the UIP and NPHCE, and organised cancer screening stops at 65.